Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.67 |
| ▸ | MMP13 | P45452 | 15/20 | 0.67 |
| ▸ | MMP9 | P14780 | 14/20 | 0.67 |
| ▸ | MMP8 | P22894 | 12/20 | 0.67 |
| ▸ | MMP1 | P03956 | 3/20 | 0.67 |
| ▸ | MMP14 | P50281 | 3/20 | 0.67 |
| ▸ | MMP16 | P51512 | 2/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.67 |
| ▸ | MMP3 | P08254 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917445 | 1.00 | MMP2 (0.67) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3914722 | 0.90 | MMP2 (0.67) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3914725 | 0.90 | MMP2 (0.67) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3916340 | 0.87 | MMP2 (0.60) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3916339 | 0.87 | MMP2 (0.60) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL15199461 | 0.87 | MMP2 (0.69) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3912596 | 0.87 | MMP2 (0.62) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3912599 | 0.87 | MMP2 (0.62) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3918678 | 0.86 | MMP2 (0.61) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL3918676 | 0.86 | MMP2 (0.61) | MMP2MMP13MMP9MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504537-B2 | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1466899-A1 | HYDROXAMIC ACID DERIVATIVE AND MMP INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | MMP13, MMP3, MMP2 | MMP2 3/4885MMP13 1/4885MMP9 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.